Yan Leyfman: 3-Year Update of TRANSFORM Trial
Yan Leyfman, Co-founder and Executive Director of MedNews Week, posted on X:
“3-Year TRANSFORM Trial Update.
For 2L primary refractory/early relapsed LBCL, liso-cel continues to outperform standard of care (SOC).
Key Results (Median follow-up: 33.9 mo):
- EFS: 29.5 mo (liso-cel) vs 2.4 mo (SOC)
- PFS: Not reached vs 6.2 mo
- 3-yr PFS: 51% vs 26.5%
- 3-yr OS: 63% vs 52% (adjusted HR 0.566 with crossover)
- Durable efficacy
- Favorable safety
- Curative potential.”
Title: Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study
Authors: Manali Kamdar, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahim, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Victor A. Chow, Sandrine Montheard, Josu Santamaria, Silvia Colicino, Ken Ogasawara, Lara Stepan, Fei Fei Liu, Jeremy S. Abramson
Read The Full Article at Journal of Clinical Oncology.
More posts featuring Yan Leyfman on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023